Abstract | BACKGROUND: METHODS: Patients with upper abdominal pain suggesting pancreatic disease (persistent over hours, pain aggravated by ingestion of food, epigastric pain radiating to the back), without a history of alcohol consumption and who exhibited no abnormalities regarding serum amylase and lipase, ultrasonography, CT and upper gastrointestinal endoscopy, were prescribed 200 mg camostat mesilate three times daily for 2 weeks. The patients were subjected to endoscopic ultrasonography (EUS) while under treatment and were distributed into those who had 4 or more suggestive findings of chronic pancreatitis (suspected pancreatic disease group), 2 or 3 (equivalent group) and those with 1 or no findings (control group). Symptom severity was recorded before and after treatment using a 10-cm visual analog scale (VAS). RESULTS: Among 95 patients, 40 were in the suspected pancreatic disease group, 30 were in the equivalent group and 25 served as controls. A significant intra- and intergroup improvement of symptoms was observed not only in the suspected pancreatic disease group but also in the equivalent group. CONCLUSIONS:
|
Authors | Jin Kan Sai, Masafumi Suyama, Yoshihiro Kubokawa, Yuji Matsumura, Koichi Inami, Sumio Watanabe |
Journal | Journal of gastroenterology
(J Gastroenterol)
Vol. 45
Issue 3
Pg. 335-41
(Mar 2010)
ISSN: 1435-5922 [Electronic] Japan |
PMID | 19876587
(Publication Type: Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Esters
- Guanidines
- Protease Inhibitors
- camostat
- Gabexate
|
Topics |
- Abdominal Pain
(diagnosis, drug therapy, etiology)
- Adult
- Aged
- Dyspepsia
(diagnosis, drug therapy, etiology)
- Endosonography
(methods)
- Esters
- Female
- Gabexate
(analogs & derivatives, pharmacology)
- Guanidines
- Humans
- Male
- Middle Aged
- Pain Measurement
- Pancreatic Diseases
(diagnosis, drug therapy, physiopathology)
- Prospective Studies
- Protease Inhibitors
(pharmacology)
- Severity of Illness Index
- Treatment Outcome
|